However, the patients with EGFR mutations only account for 10–35 percent of NSCLC patients and the frequency of EML4-ALK fusion patients is just 5–7 percent5, meaning that the remaining patients still need to rely on platinum-based chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.